论文部分内容阅读
目的 评价干扰素α1b联合拉米夫定治疗慢性乙型肝炎的近期疗效。方法 17例HBVDNA及HBeAg阳性的慢性乙型肝炎病人接受干扰素α1b联合拉米夫定治疗 6个月 ,并与 2 1例仅接受干扰素α1b的病人进行对比。观察联合用药组与单一用药组的谷丙转氨酶、HBVDNA、HBeAg的变化情况及副作用。结果 联合用药组的谷丙转氨酶复常率为 88 2 % ,HBeAg的转阴率为 6 4 7% ;单一用药组分别为 85 7%和5 7 1%。两组比较差异无显著意义。联合用药组的HBVDNA转阴率为 88 2 % ,而单一用药组为 5 7 1% ,两组比较差异有显著意义 (P <0 0 5 )。结论 干扰素α1b和拉米夫定联合应用是一种较安全、有效的方法
Objective To evaluate the short-term curative effect of interferon α1b combined with lamivudine in the treatment of chronic hepatitis B patients. Methods Seventeen patients with HBVDNA and HBeAg-positive chronic hepatitis B received interferon alb and lamivudine for 6 months and were compared with 21 patients who received interferon alb only. To observe the changes and side effects of alanine aminotransferase, HBVDNA and HBeAg in the combined group and single group. Results The normalization rate of alanine aminotransferase in the combination group was 88.2%, the negative conversion rate of HBeAg was 64.7%, that of the single group was 85.7% and 57.1% respectively. There was no significant difference between the two groups. The HBVDNA negative rate in the combination group was 88.2%, while that in the single drug group was 57.1%. There was significant difference between the two groups (P <0.05). Conclusion The combination of interferon α1b and lamivudine is a safe and effective method